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Abstract
Background The main cause of chronic pancreatitis (CP)
is excessive alcohol consumption. On the other hand, only
5–10% of heavy drinkers develop chronic pancreatitis. We
have only limited information regarding the pathogenic
mechanism by which alcohol leads to the disease. Muta-
tions of the PRSS1 and SPINK 1 have been mostly
implicated in hereditary and idiopathic CP, but their pres-
ence in other types of this disease have also been reported.
Aims The aim of the study was to determine the fre-
quency of PRSS1 and SPINK1 mutations in patients
with chronic alcoholic (ACP) and idiopathic pancreatitis
(ICP) as well as to investigate their relation to the clinical
course of the disease.
Methods Thestudyincluded33ACPand14ICPpatientsas
well 46 healthy subjects. The diagnosis of CP was based on
clinical data, ultrasound, and computed tomography. After
isolation of DNA from peripheral blood two trypsinogen
mutations were detected N29I and R122H by allelo-speciﬁc
ampliﬁcation polymerase chain reaction (ASA-PCR) and by
the PCR-restriction fragment length polymorphism (RFLP).
Beside this N34S mutation of SPINK1 was analyzed by PCR
restriction fragment length polymorphism (PCR-RFLP).
Results PRSS1 mutations have been detected in 11 (33%)
patients with ACP. The frequency of the PRSS1 mutations
was higher in patients with ACP than in controls (4.3%)
(p\0.001). The frequency of PRSS1 mutation was present
in 21.4% of ICP patients, which was signiﬁcantly higher
(p\0.05) than in controls. Overall, six (18%) SPINK1
mutations in ACP group have been detected. Among 14
patients withICP,in four (28.6%) of them SPINK1 has been
detected. The same mutations have also been found in three
(6.5%)controlsubjects.ThefrequencyoftheN34Smutation
was higher in patients with ICP than in the controls (p\
0.05), but the frequency of N34S mutation did not differ
between ACP and the control group. No relations have been
detected between PRSS1 and SPINK1 mutations presence
and clinical course and complications of CP.
Conclusions Those preliminary data suggest the high
prevalence of SPINK1 and PRSS1 mutations in the Polish
population, generally, as well as in CP patients. It may be
speculated that those mutations contribute to the develop-
ment of chronic pancreatitis, especially in patients with
alcohol overindulgence.
Keywords Alcoholic chronic pancreatitis   Idiopathic
chronic pancreatitis   SPINK1   PRSS1
A. Gasiorowska (&)   R. Talar-Wojnarowska  
E. Malecka-Panas
Department of Digestive Tract Diseases, Medical University
of Lodz, Kopcinskiego 22, 90-153 Lodz, Poland
e-mail: anita@sofcom.pl
R. Talar-Wojnarowska
e-mail: renata.talar-wojnarowska@umed.lodz.pl
E. Malecka-Panas
e-mail: ewuncia@poczta.onet.pl
L. Czupryniak
Diabetology and Metabolic Diseases, Medical University
of Lodz, Kopcinskiego 22, 90-153 Lodz, Poland
e-mail: bigosik@poczta.onet.pl
B. Smolarz   H. Romanowicz-Makowska   A. Kulig
Laboratory of Molecular Genetics, Institute of Polish Mother’s
Memorial Hospital, Rzgowska 281/289, 93-338 Lodz, Poland
e-mail: smolbea@wp.pl
H. Romanowicz-Makowska
e-mail: hanna.romanowicz-makowska@umed.lodz.pl
A. Kulig
e-mail: andrzej.kulig@umed.lodz.pl
123
Dig Dis Sci (2011) 56:894–901
DOI 10.1007/s10620-010-1349-4Introduction
Chronic pancreatitis (CP) is a disease characterized by
recurrent episodes of abdominal pain accompanied by
progressive pancreatic exocrine and endocrine insufﬁ-
ciency [1, 2]. In the Western countries, alcohol is generally
considered an important risk factor for the development of
chronic pancreatitis [3]. In addition, other metabolic, ana-
tomical, obstructive, and autoimmune etiological factors
have also been recognized [1, 4]. Furthermore, in recent
years, several genetic risk factors for chronic pancreatitis
have been identiﬁed. Nevertheless, around one-third of all
patients have no etiological factor recognized, and these
cases are classiﬁed as idiopathic chronic pancreatitis (ICP)
[5]. Despite earlier suggestions that the clinical course of
CP depends on its etiology, the ﬁnal clinical and histo-
logical presentation of the disease is similar in most cases
[5, 6].
The pathogenesis of CP is still only partially under-
stood. Several mechanisms such as duct obstruction by
protein plugs, direct toxicity of ethanol, or oxidative stress
have been proposed [1, 2]. Furthermore, the exact
mechanism of alcoholic pancreatitis is not known. Since
only 5–10% of heavy drinkers develop the disease,
numerous studies suggest that alcohol represents only a
risk factor for developing pancreatic inﬂammation in
genetic or environmentally predisposed subjects [7].
Whitcomb et al. [8] discovered mutations in the cationic
trypsinogen gene (PRSS1) in families with hereditary
pancreatitis, which stimulated the search for genetic fac-
tors predisposing to pancreatic disease. Some mutations in
the PRSS1 gene are thought to prevent the inactivation of
trypsin within the pancreas, leading to autodigestion and
pancreatitis. Two mutations, R122H and N29I in the
human cationic trypsinogen gene (PRSS1) have been
detected in 14–68% of the hereditary pancreatitis (HP)
patients [8–12]. Mutations of those genes have been
particularly implicated in hereditary pancreatitis, but their
presence in disease of other etiologies have also been
reported [13–15].
Pancreatic secretory trypsin inhibitor (PSTI), also
known as serine protease inhibitor Kazal type1, (SPINK1),
was suggested to be the ﬁrst line of defense against pre-
mature trypsin activation in the pancreas [16]. Mutation in
the SPINK1 gene was ﬁrst shown to be associated with
chronic pancreatitis in children and adolescents, and sub-
sequently with many other forms of pancreatitis, including
alcoholic pancreatitis [17–19]. In the former study, Witt
and colleagues described that N34S mutation was present
in 18 (19%; six homozygotes and 12 heterozygotes) of 96
patients who did not carry any of the PRSS1 mutations
[17]. In subsequent investigations, the N34S mutation of
the serine protease inhibitor, Kazal type 1 (SPINK1), has
been reported to have a connection with idiopathic and
hereditary chronic pancreatitis [16, 20–22].
The aim of the study was to determine the frequency of
PRSS1 and SPINK1 mutations in patients with alcoholic
chronic pancreatitis (ACP) and idiopathic chronic pancre-
atitis (ICP) compared to healthy volunteers. We also
reviewed the clinical data of CP patients and analyzed the
severity of the disease with PRSS1 and SPINK1 mutations.
Materials and Methods
Patients
Patients were recruited from the Department of Digestive
Tract Diseases, Medical University of Lodz. DNA analysis
was obtained from blood samples and performed at the
Laboratory of Molecular Genetics, Department of Pathol-
ogy, Institute of Polish Mother’s Memorial Hospital, Lodz,
Poland.
A total of 47 patients with chronic pancreatitis were
included in the present investigation: 33 with alcohol-
related disease, and 14 with idiopathic disease. All patients
were Caucasian.
The diagnosis of CP was based on the following criteria
[4]:
• presence of a typical history of recurrent attacks of
pancreatitis
• anatomical abnormalities such as calciﬁcations and/or
pancreatic ductal irregularities present in ultrasound
and computed tomography.
ACP (alcoholic chronic pancreatitis) was diagnosed in
patients who consumed more than 80 g/day of alcohol
(males) and at least 40 g/day of alcohol (females) for 5 or
more years, before the ﬁrst symptoms of the disease [4].
ICP (idiopathic chronic pancreatitis) was diagnosed
when possible etiological factors such as alcohol abuse and
positive family history were absent [4]. Other possible risk
factors for the development of chronic pancreatitis were
evaluated through laboratory tests (hypercalcemia, hyper-
triglyceridemia) and by radiology (magnetic resonance
cholangiopancreatography), including that of both the bil-
iary and pancreatic ducts.
The associations of the analyzed mutations and clinical
data have been evaluated. The following demographic and
clinical data were analyzed: age, age of onset of CP, gen-
der, history of smoking, and endocrine insufﬁciency. The
onset of chronic pancreatitis was deﬁned as the initial
manifestation—ﬁrst episode of acute pancreatitis. For the
purpose of this study, smokers were deﬁned as those who
smoked ten or more cigarettes per day for at least 2 years.
The diagnosis of diabetes mellitus was made according to
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was well established and treated some time prior to the
enrollment to the study. Clinical data collected also
included endoscopic (lithotripsy, endoscopic pancreatic or
biliary stenting, and pseudocysts drainage) or surgical
(pancreaticoduodenectomy, distal pancreatectomy, and
pseudocyst drainage) treatment due to CP complications.
The demographic and clinical data of the 47 patients
with chronic pancreatitis was divided into two groups: ACP
and ICP, and are presented in Table 1. There were no
differences in age between the two groups (ACP 46 ± 9
vs. ICP 42 ± 14 years). The majority of patients in the
ACP group were male (n = 29; 88%) as compared to the
ICP group (n = 6; 43%), (p\0.01). The median age of
onset of the symptoms was 41 years (range 26–66) in
patients with ACP, and 37 years (range 17–56) in patients
with ICP. In the ICP group, in two patients the onset of
disease was under 20 years.
The control group consisted of 46 healthy subjects (30
males, 16 females; mean ± SD age: 35.0 ± 17.9 years,
range: 21–77).
The study was undertaken under strict ethical guidelines
and involved written consent of every participant. Patients
were asked for informed consent to document their clinical
data. The study was approved by the local ethics committee
of the Medical University of Lodz.
Methods
DNA Extraction
Peripheral venous blood samples were obtained from all
analyzed patients at the time of hospital admission and from
the control group subjects. Genomic DNA was extracted
from anticoagulated blood samples using the spin column
method(QIAampDNABloodMiniKits;Qiagen,Germany)
according to the manufacturer’s recommendations.
PRSS1 Mutation Detection
The R122H mutation was detected by the method PCR-
RFLP (polymerase chain reaction-restriction fragment
length polymorphism) using speciﬁc primer sequences:
50 GGT CCT GGG TCT CAT ACC TT 30 and 50 GTA
ATG GGC ACT CGA AAT GT 30. PCR was performed
using 2 ll of genomic DNA template, 1 U of Taq poly-
merase (TaKaRa, BIOKOM), a 0.2 lM concentration of
each primer, 2.5 ll of buffer, a 50 lM concentration of
each dNTP in a 25-ll reaction volume. Thirty-ﬁve cycles
of PCR were performed (30 s at 94 C, 30 s at 60 C, 30 s at
72 C) and ﬁnal extension for 5 min at 72 C in an auto-
mated thermal cycler GeneAmp PCR 2400 (Perkin Elmer,
Norwalk, USA). The PCR products were then digested
with restriction endonulcease BbrPI for 2 h at 37 C. The
digested ampliﬁcation products were electrophoresed on
7% polyacrylamide gel (PAGE) and stained with ethidium
bromide, generating two fragments of 327 bp and 228 bp.
After digestion, the obtained product had an additional
length of 208 bp.
The N29I mutation of exon 2 was detected by the PCR
ampliﬁcation using speciﬁc primer sequences: 50 CCAT
CTTACCCAACCTCAGTAG 30 and 50 TGATGACA-
GATCGTTGGGGGCTAGA 30. The reaction program was
as follows: an initial denaturation for 5 min at 94 C, and an
additional 35 cycles of 30 s denaturing at 94 C; 30 s of
hybridization for 30 s at 56 C, 45 s of primer extension at
72 C; and a ﬁnal extension for 10 min at 72 Ci na n
automated thermal cycler GeneAmp PCR 2400 (Perkin
Elmer, Norwalk, USA). The products were then digested
with restriction endonulcease Sau3A. PCR-ampliﬁed
products were electrophoretically separated on 7% poly-
acrylamide gel (PAGE) and stained with ethidium bromide.
In the presence of N29I mutation, two bands of 207 and
23 bp were seen, whereas only one band of 1,018 bp was
seen on the gel.
SPINK1 Mutation Detection
DNA samples from the patients and the control subjects
were analyzed for a common mutation of SPINK1. The
N34S mutation of exon 3 was detected by PCR-restriction
fragment length polymorphism (RFLP) using speciﬁc pri-
mer sequences: 50 TTC TGT TTA ATT CCA TTTTT AGG
CCA AAT GCT GCA 30 and 50 GGC TTTT ATC ATA
CAA GTG ACT TCT 30. The primers were designed to
introduce a PstI endonuclease restriction site in sequences
containing the N34S mutation and BsrDI endonuclease
restriction site in wild-type sequences. PCR was performed
using 2 ll of genomic DNA template, 1 U of Taq poly-
merase (TaKaRa, BIOKOM), a 0.2 lM concentration of
each primer, 2.5 ll of buffer, a 50 lM concentration of
each dNTP, and 25-ll reaction volume. Thirty-ﬁve cycles
of PCR were performed (30 s at 94 C, 30 s at 60 C, and
60 s at 74 C) in an automated thermal cycler GeneAmp
PCR 2400 (Perkin Elmer, Norwalk, USA). The PCR
Table 1 Characteristics of the study population
Alcoholic
chronic
pancreatitis (n = 33)
Idiopathic
chronic
pancreatitis
(n = 14)
p
Sex (M/F) 29 (88%)/4 (12%) 6 (43%)/8 (57%) \0.01
Mean age
(mean ± SD)
46 ± 94 2 ± 14 NS
Age of onset (years) 41 (26–66) 35 (17–56) NS
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123products were then digested with restriction endonulcease
PstI and BsrDI. Undigested ampliﬁcation products were
320 bp long. After digestion with PstI, a product of 286 bp
was obtained from mutant sequences, and an identical
result was achieved from wild-type sequences after diges-
tion with BsrDI. Heterozygote samples produced products
of both 320 and 286 bp after digestion with either endo-
nuclease. PCR-ampliﬁed products were electrophoretically
separated on 7% polyacrylamide gels (PAGE) and stained
with ethidium bromide.
Statistical Analysis
Statistical analysis was performed using the STATISTICA
for Windows package (8.0 version PL, #AXXP2075488424
D60, StatSoft, Tulsa, Okla., USA). Differences between
means of continuous variables (e.g., age) were analyzed by
Student’s t test for unpaired data unless their distribution
was not found normal with Kolmogorov and Lillefors’
tests, in which case the Mann–Whitney U test was used.
Differences in mutations distribution were analyzed by the
non-parametric v
2 test, when necessary—i.e., when cases
number in a subgroup was \5—with Yates’ correction.
If cases number in a subgroup was zero, the exact Fisher
test was employed. The measurements were expressed as
means (±SD). Values of p\0.05 were considered
signiﬁcant.
Results
Mutational Analysis of PRSS1
Analysis of the cationic trypsinogen gene revealed 14
mutations in 11 patients (23.4%) among 47 individuals
with chronic pancreatitis and two mutations (4.3%) in the
control group.
Generally, in the ACP group, 11 PRSS1 mutations were
found in eight patients. In the ICP group, three PRSS1
mutations were carried by three patients. The cationic
trypsinogen R122H mutation affected seven patients (21%)
from the ACP group and two patients (14%) from the ICP
group, respectively. The next assessed PRSS1 mutation,
namely N29I, was present in four patients with ACP (12%)
and in one patient with ICP (7%).
Three patients from the ACP (9%) group had both the
R122H and N29I cationic trypsinogen gene mutations.
The frequency of the PRSS1 mutations was higher in
patients with ACP than in controls (33 vs. 4.3%;
p\0.001; OR was 11.0 (CI 2.47–47.73). The frequency of
PRSS1 mutation was present in 21.4% of ICP patients
which was signiﬁcantly higher (p\0.05) than in controls
(4.3%); OR was 6.0 (CI 1.05–33.93).
Otherwise, three patients, two from the ICP group and
one from the ACP group had cationic trypsinogen gene
(R122H) and N34S SPINK1 mutations.
Mutational Analysis of SPINK1
Mutational analysis of SPINK1 N34S in all chronic pan-
creatitis patients and controls was performed. Ten indi-
viduals with CP (21.3%) and three (6.5%) from the control
group carried the N34S mutation (p[0.05).
Among the CP group, in six patients (18%) with alco-
holic CP and four patients (28.6%) with idiopathic CP
N34S mutation of the SPINK1 was detected. The fre-
quencies of the N34S mutation in patients with ACP and
ICP were similar. However, the frequency of the N34S
mutation was higher in patients with ICP than in controls
(p\0.05). Odds ratio (OR) for the N34S mutation
occurrence in idiopathic CP was 5.73; 95% conﬁdence
interval (CI): 1.22–26.96.
In both ACP and ICP patients, the frequency of het-
erozygotes and homozygotes was equal, three (9%) and
two (14.3%), respectively. Two individuals from the ICP
group (14%) were heterozygous and two homozygous for
the mutation. In the control group, one homozygote (2%)
and two heterozygotes (4%) have been detected. The fre-
quency of N34S heterozygote or homozygote did not differ
between the ACP, ICP, or control groups.
The frequency of the PRSS1 and SPINK1 mutations in
the different groups are summarized in Table 2.
Clinical Courses of Chronic Pancreatitis and Mutations
Moreover, we evaluated the clinical course of ACP and
ICP depending on different mutations present (Tables 3, 4).
We reviewed the clinical course, including diabetes mel-
litus, calciﬁcation, pseudocysts, changes of the main pan-
creatic duct, cholestasis, and therapeutic intervention.
We did not ﬁnd any signiﬁcant difference of the clinical
course between the ACP patients with and without PRSS1
mutations. The frequency of diabetes, as well as the fre-
quency of calciﬁcation, were not different between the
SPINK1 mutation-positive and -negative ACP patients.
Patients carrying the N34S mutation had the same fre-
quency of abnormal main pancreatic duct and pseudocysts.
Patients carrying the N34S mutation did not require sur-
gical and/or endoscopic intervention more often than those
without the mutations.
The difference between the frequency of diabetes in ICP
patients with and without SPINK1 and PRSS1 mutations
did not approach statistical signiﬁcance. Four patients
having the SPINK1 mutation and one individual carrying
the R122H mutation had severe pancreatitis as deﬁned by
morphological alterations in the pancreas, such as duct
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The structural pancreatic changes in imaging techniques
were similar in both groups (with and without mutations).
Furthermore, no speciﬁc association was noted between
any therapeutic intervention used in ICP patients and gene
mutations.
Discussion
Several studies have investigated the role of the cationic
trypsinogen gene and serine protease inhibitor Kazal type1
as an etiologic factor of pancreatitis. To our knowledge,
this is the ﬁrst study to determine the frequency of
mutations in the PRSS1 and SPINK1 in Polish adult
patients with chronic pancreatitis. The results of our study
suggest the high incidence of SPINK1 and PRSS1 muta-
tions in Polish population generally as well as in CP
patients. In the study of our population, the PRSS1 muta-
tions were detected in eight (24%) ACP patients and in
three (21%) ICP patients. However, N34S mutation was
found in six (18%) patients with ACP and four (28.6%)
patients of ICP.
In Poland, only in Polish Institute of Mother and Child
in Warsaw, the chronic pancreatitis and acute recurrent
pancreatitis (ARP) in children and their family members
were analyzed focusing exclusively on the mutations
screening of PRSS1, SPINK1, CFTR (Cystic Fibrosis
Table 2 Distribution of the PRSS1 and SPINK1 mutations in affected individuals and the control group
N34S PRSS1
Total Heterozygotes Homozygotes Total R122H N29I
Alcoholic chronic pancreatitis (ACP) (n = 33) 6 (18%) 3 3 11
b (33%) 7 4
Idiopathic chronic pancreatitis (ICP) (n = 14) 4
a (28.6%) 2 2 3
c (21.4%) 2 1
Control group (n = 46) 3
a (6.5%) 2 1 2
b,c (4.3%) 0 2
a Statistical difference between frequency of N34S mutation in ICP compared to the control group (p\0.05)
b Statistical difference between frequency of PRSS1 mutations in ACP compared to the control group (p\0.01)
c Statistical difference between frequency of PRSS1 mutations in ICP compared to the control group (p\0.05)
Table 3 Comparison of clinical
data of ACP patients with and
without SPINK1 and PRSS1
mutations (p[0.05)
Mutated
SPINK1
(n = 6)
Mutation
negative
(n = 27)
p Mutated
PRSS1
(n = 11)
Mutation
negative
(n = 22)
p
Diabetes mellitus 3 12 NS 8 7 NS
Calciﬁcations 3 8 NS 6 5 NS
Pseudocysts 2 13 NS 6 9 NS
Abnormal main pancreatic duct 3 5 NS 3 5 NS
Cholestasis 2 9 NS 4 7 NS
Endoscopic treatment 2 11 NS 6 7 NS
Surgical treatment 2 5 NS 3 4 NS
Chronic use of analgesics 2 12 NS 8 6 NS
Table 4 Comparison of clinical
data of ICP patients with and
without SPINK1 and PRSS1
mutations (p[0.05)
Mutated
SPINK1
(n = 4)
Mutation
negative
(n = 10)
p Mutated
PRSS1
(n = 3)
Mutation
negative
(n = 11)
p
Diabetes mellitus 0 2 NS 1 10 NS
Calciﬁcations 3 4 NS 1 7 NS
Pseudocysts 1 1 NS 1 1 NS
Abnormal main pancreatic duct 0 7 NS 0 7 NS
Cholestasis 0 5 NS 1 4 NS
Endoscopic treatment 0 7 NS 1 6 NS
Surgical treatment 1 3 NS 0 4 NS
Chronic use of analgesics 2 2 NS 0 4 NS
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(a1-antitrypsin) [23]. In this study, PRSS1 mutations were
identiﬁed mainly in CP patients, whereas N34S SPINK1
mutation was present with comparable frequency in CP and
ARP patients.
Whitcomb et al. [8] conducted extensive mutational
analysis of cationic trypsinogen gene in hereditary pan-
creatitis (HP) patients and their families throughout the
world. The ﬁrst pathogenic mutation in the human cationic
trypsinogen gene (protease serine 1; PRSS1), a missense
mutation (R122H) in exon 3 was reported. Other mutations
in this gene, also associated with hereditary pancreatitis
such as N29I, A16V, R122C, and D22G, were observed by
other groups [8, 9, 11–13].
Although the PRSS1 mutations have shown an
involvement with HP, they can also be found in a variable
incidence (0–19%) in idiopathic chronic pancreatitis [13,
15, 24]. In our study, we found R122H mutation in two
patients (14%) and N29I mutation in one patient (7%) with
idiopathic CP. The frequency of PRSS1 mutations in ICP
patients was found to be signiﬁcantly higher (21%) com-
pared to the control group (4.3%). There was no evidence
of a family history of pancreatitis or pancreatic cancer in
our patients. Witt et al. [10], analyzing the complete coding
region of the cationic trypsinogen gene, found the A16V
mutation in 10% patients with idiopathic pancreatitis from
Germany. None of these patients had a family history of
CP. The authors concluded that evaluation of patients with
CP should include genetic testing for mutations in the
cationic trypsinogen gene even in the absence of a family
history of pancreatitis. Similarly, Simon et al. [25] found a
trypsinogen mutation in ﬁve of 50 patients with idiopathic
pancreatitis from Munster University Hospital. All patients
had the R122H mutation. They also revealed that patients
with trypsinogen mutations were signiﬁcantly younger at
disease onset (mean age: 14 ± 3 years) than the remaining
cohort (38 ± 2 years) of patients. Recently, Grocock et al.
[26] described the phenotypes that are associated with
A16V mutation of PRSS1, but they didn’t ﬁnd differences
compared to affected individuals with R122H and N29I
mutations.
There are, however, limited data regarding frequency of
PRSS1 mutations in ACP patients from different ethnic
groups. In a Brazilian study, no mutation in the PRSS1
gene was detected in patients with a family history of
pancreatitis, but the E79K mutation in the PRSS1 gene
change in exon 3 was identiﬁed in one patient (1.56%) with
alcohol-related chronic pancreatitis [27]. O’Reilly et al.
[15], in a study from the United Kingdom, described the
R122H mutation in one patient from the ACP group
(2.8%), however the N29I, A16V and –28delTCC muta-
tions were not detected in any of the study subjects. Teich
et al. [28] from Germany did not ﬁnd N21I and R117H
mutations of the cationic trypsinogen gene assessing in
leukocyte DNA, in pancreatic juice and in the pancreatic
tissue DNA from patients with ACP. In other studies from
India [19], the Netherlands [21], and from the USA [29], no
cationic trypsinogen mutation genes were identiﬁed in any
of the ACP patients. Despite the fact that several studies
failed to detect greater frequency of the PRSS1 mutations
in ACP patients, we have found these mutations in as much
as 33% of ACP patients [14, 15, 30, 31].
The association between SPINK1 mutations and the
incidence of chronic pancreatitis in alcoholics has been
controversial. In several studies, the SPINK1 N34S muta-
tion was reportedly slightly increased in patients with
alcoholic pancreatitis as compared to controls [18, 21, 30,
32]. Witt et al. [33] reported a 5.8% prevalence of N34S
SPINK1 in ACP patients, thus implicating mutated
SPINK1 in its pathogenesis. Recently, patients with acute
pancreatitis were also evaluated and the SPINK1 gene
mutation was found in 7.8% of patients—the majority of
them had alcohol-induced AP [34]. However, in the study
performed by Lempinen et al. [18], a higher frequency
(10%) of the SPINK1 N34S mutation in patients with
alcoholic CP was detected. In contrast to these studies,
Chandak et al. [19] found a highly signiﬁcant prevalence of
SPINK1 mutations in a cohort of ACP patients from India
(26.8%). On the other hand, in a Korean population,
occurrence of the SPINK1 N34S mutation in control pop-
ulation and patients with alcoholic pancreatitis was less
common than in Western reports [35]. These discrepancies
might obviously result from the genetic diversity in dif-
ferent ethnic groups. In our study, the frequency of the
SPINK1 mutation in ACP was 18%, which was higher than
that observed in several reports from Europe and the USA.
The N34S mutation was detected in three patients (6.5%)
from our control group, which is higher than in other
reports (0–2.8%) [32, 36–38].
The frequency of the SPINK1 mutations in ICP showed
a discrepancy in different reports ranging from 6.4% in
French patients [39], 25% of patients from Finland [18]t o
as high as 40% in patients from the USA and The European
Registry of Hereditary Pancreatitis and Familial Pancreatic
Cancer (EUROPAC) Recruitment [20]. In a study by
Pfutzer et al. [20], seven homozygous (12%) and 14 het-
erozygous (25%) N34S mutations in a series of 57 ICP
patients were reported. These patients were recruited for
genetic analysis in the United States and Europe but were
negative for PRSS1 mutations. The authors suggested that
the mutated SPINK1 gene behaves as a disease-modiﬁer
gene. Another study from Germany and Switzerland
demonstrated a strong association of SPINK1 gene muta-
tion and ICP, especially with the early onset type [40].
In our study, the frequency of SPINK1 mutations in
patients with idiopathic CP was 28.6%, which is in line
Dig Dis Sci (2011) 56:894–901 899
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SPINK1 mutations with idiopathic CP [17, 20].
It remains unknown whether the SPINK1 and PRSS1
mutations have an impact on the clinical course of CP. Our
study, with a relatively limited number of patients, failed to
reveal any association between mutations and the more
severe form of chronic pancreatitis. Similar results were
observed in other studies, including patients with ACP with
and without SPINK1 mutation from the USA [32]. The
authors concluded that presence of genetic variations in the
SPINK1 gene does not appear to have a dominant effect on
the clinical phenotype of alcoholic pancreatitis. In another
study in ICP patients, the disease course was similar with
regard to the development of calciﬁcations and exocrine
and endocrine insufﬁciency in early onset ICP patients with
or without a heterozygous SPINK1 mutation [40]. In con-
trast, Masamune et al. [41] have shown in patients with
non-alcoholic pancreatitis that those carrying the N34S
mutation presented with more severe disease compared to
ones without SPINK1 mutations. This study conﬁrmed the
previous report by Pfutzer et al. [20] showing that the
SPINK1 mutations predisposed patients to an earlier age of
disease onset. Other authors found a tendency for the N34S
mutation to be more common in patients with severe acute
pancreatitis, but it failed to reach statistical signiﬁcance
[34]. Creighton et al. [41] evaluated the correlation of
R117H mutation and clinical data of CP. They showed that
this mutation was associated with a more severe form of
HP in terms of age at onset of symptoms and requirement
for surgical intervention. Finally, it might be added that
results of a study by Keim et al. [42] showed that pro-
gression of chronic pancreatitis was slightly more rapid in
patients with SPINK1 mutations than in patients with cat-
ionic trypsinogen mutations. In comparison to alcoholic
chronic pancreatitis patients, the PRSS1 associated disease
revealed a lower frequency of calciﬁcation and diabetes.
Some unresolved issues remain, including the high fre-
quency of PRSS1 mutations in our CP patients. There are
many clinical similarities of symptoms between chronic
alcoholic and hereditary pancreatitis. When the onset of
symptoms in patients with the inherited disease is late, and
when a familial relationship is not obvious, it may be
difﬁcult to differentiate the two forms of CP. It cannot be
excluded that patients have relatives affected but not fully
diagnosed. Although susceptibility to alcoholic pancreatic
damage could be inherited, until now no clear association
between any gene mutation(s) and occurrence of ACP in
alcoholics has been reported. Perri et al. [30] performed
mutation analysis on the PRSS1, the CFTR, and the
SPINK1 genes in Italian patients with ACP compared to
patients from the same geographical area who were
affected by alcoholic liver disease without any clinically
recognized pancreatic disease. This study shows that
mutations in PRSS1, CFTR, and SPINK1 genes are only
occasionally found in patients with ACP, and their preva-
lence is not signiﬁcantly increased in comparison to alco-
holics who develop alcoholic liver disease.
In conclusion, the frequency of PRSS1 mutations in ICP
and ACP patients in Poland was higher than that reported
in previous European studies. The frequency of the
SPINK1 N34S mutation in patients with idiopathic CP was
similar to that in many earlier studies but was higher in
Polish patients with alcoholic CP compared to other studies
and populations. The latter ﬁnding could be associated with
a signiﬁcantly higher population frequency of the N34S
mutation in Poland than in other geographical regions.
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